CA3000851A1 - Rational combination therapy for the treatment of cancer - Google Patents

Rational combination therapy for the treatment of cancer Download PDF

Info

Publication number
CA3000851A1
CA3000851A1 CA3000851A CA3000851A CA3000851A1 CA 3000851 A1 CA3000851 A1 CA 3000851A1 CA 3000851 A CA3000851 A CA 3000851A CA 3000851 A CA3000851 A CA 3000851A CA 3000851 A1 CA3000851 A1 CA 3000851A1
Authority
CA
Canada
Prior art keywords
cancer
hsp90
inhibitor
administered
proteotoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3000851A
Other languages
English (en)
French (fr)
Inventor
Gabriela Chiosis
Tony Taldone
Liza SHRESTHA
John KOREN
Erica M. Gomes-Dagama
Anna Rodina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CA3000851A1 publication Critical patent/CA3000851A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3000851A 2015-10-05 2016-10-05 Rational combination therapy for the treatment of cancer Abandoned CA3000851A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562237470P 2015-10-05 2015-10-05
US62/237,470 2015-10-05
PCT/US2016/055594 WO2017062520A1 (en) 2015-10-05 2016-10-05 Rational combination therapy for the treatment of cancer

Publications (1)

Publication Number Publication Date
CA3000851A1 true CA3000851A1 (en) 2017-04-13

Family

ID=57145064

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3000851A Abandoned CA3000851A1 (en) 2015-10-05 2016-10-05 Rational combination therapy for the treatment of cancer

Country Status (14)

Country Link
US (1) US20180280397A1 (enExample)
EP (1) EP3359196B1 (enExample)
JP (1) JP7132848B2 (enExample)
KR (1) KR20180058824A (enExample)
CN (1) CN108472376A (enExample)
AU (1) AU2016336351A1 (enExample)
BR (1) BR112018006572A2 (enExample)
CA (1) CA3000851A1 (enExample)
EA (1) EA201890623A1 (enExample)
IL (1) IL258494A (enExample)
MA (1) MA47474A (enExample)
MX (1) MX2018004112A (enExample)
TW (1) TW201722422A (enExample)
WO (1) WO2017062520A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016008418A (es) 2013-12-23 2017-01-11 Memorial Sloan Kettering Cancer Center Metodos y reactivos para el radiomarcaje.
CN110090303B (zh) * 2019-05-07 2022-09-16 浙江大学 阿片受体激动剂在制造用于治疗恶性肿瘤的药物中的用途
CN112641949A (zh) * 2021-01-11 2021-04-13 深圳市人民医院(深圳市呼吸疾病研究所) 一种含有pi3k抑制剂的药物组合物及其应用
US20240371465A1 (en) * 2023-05-02 2024-11-07 National Central University Method, system, and computer readable medium for post-translational modifications detection
CN116813622B (zh) * 2023-05-19 2026-02-03 中国科学院基础医学与肿瘤研究所(筹) 一种基于分子伴侣hsp90介导的靶向降解gpx4的嵌合体及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004512381A (ja) 2000-11-02 2004-04-22 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｈｓｐ９０インヒビターの使用により細胞毒性剤の効力を増強させる方法
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
ES2645095T3 (es) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Research Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90
NZ623069A (en) 2009-08-17 2015-11-27 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
PT2486039T (pt) 2009-10-07 2016-09-06 Sloan Kettering Inst For Cancer Res Derivados de purina úteis como inibidores de hsp90
AU2012240077C1 (en) 2011-04-05 2017-08-10 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
MX354215B (es) 2011-04-05 2018-02-19 Sloan Kettering Inst Cancer Res Inhibidores de la proteina 90 de choque termico (hsp90).
ES2624982T3 (es) 2011-07-08 2017-07-18 Sloan-Kettering Institute For Cancer Research Usos de inhibidores etiquetados HSP90
KR102319582B1 (ko) 2013-08-16 2021-11-04 메모리얼 슬로안 케터링 캔서 센터 선택적 ｇｒｐ９４ 저해제 및 이의 용도
EA201692155A1 (ru) 2014-05-13 2017-04-28 Мемориал Слоун-Кеттеринг Кэнсэ Сентр МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ

Also Published As

Publication number Publication date
EP3359196B1 (en) 2022-03-16
MA47474A (fr) 2019-12-25
EP3359196A1 (en) 2018-08-15
WO2017062520A1 (en) 2017-04-13
BR112018006572A2 (pt) 2018-10-09
EA201890623A1 (ru) 2018-09-28
JP7132848B2 (ja) 2022-09-07
MX2018004112A (es) 2018-06-20
JP2018537519A (ja) 2018-12-20
IL258494A (en) 2018-05-31
US20180280397A1 (en) 2018-10-04
KR20180058824A (ko) 2018-06-01
TW201722422A (zh) 2017-07-01
AU2016336351A1 (en) 2018-05-10
CN108472376A (zh) 2018-08-31

Similar Documents

Publication Publication Date Title
Luo et al. Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
US20230256110A1 (en) Combination of antibody-drug conjugate and atm inhibitor
Yang et al. Nrf2 inhibitor, brusatol in combination with trastuzumab exerts synergistic antitumor activity in HER2‐positive cancers by inhibiting Nrf2/HO‐1 and HER2‐AKT/ERK1/2 pathways
US20240082218A1 (en) Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor for the treatment of cancers
US20230330243A1 (en) Combination of antibody-drug conjugate and atr inhibitor
Muñoz et al. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists
Burbridge et al. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab
KR20240024938A (ko) Kras g12c 저해제를 포함하는 약제학적 조합물 및 암의 치료를 위한 이의 용도
Jhaveri et al. A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors
EP3359196B1 (en) Rational combination therapy for the treatment of cancer
Tang et al. Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263
KR102584344B1 (ko) 병용 의약
JP6255086B2 (ja) 癌のための併用療法
Nakayama et al. Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models: Translational Therapeutics
US20220195059A1 (en) Rank Pathway Inhibitors in Combination with CDK Inhibitors
Lemjabbar-Alaoui et al. AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers
Li et al. Recent advances in developing novel anti-cancer drugs targeting tumor hypoxic and acidic microenvironments
Wu et al. Identification of a novel small-molecule inhibitor targeting TIM-3 for cancer immunotherapy
CN107847597A (zh) 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂
Spiegelberg et al. The novel anti-cMet antibody seeMet 12 potentiates sorafenib therapy and radiotherapy in a colorectal cancer model
Lee et al. A pilot study for the early assessment of the effects of BMS-754807 plus gefitinib in an H292 tumor model by [18F] fluorothymidine-positron emission tomography
Cui et al. Disulfiram alone regulates the radiosensitivity of lung cancer through NF-κB pathway and regulates the immune microenvironment after radiotherapy by targeting PD-L1 through c-Myc
HK1259690B (en) Rational combination therapy for the treatment of cancer
HK1259690A1 (en) Rational combination therapy for the treatment of cancer
BR112015013196A2 (en) combinations of a pi3k / akt inhibitor compound with a her3 / egfr inhibitor compound and methods of use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211005

FZDE Discontinued

Effective date: 20240318